Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Three months ended July 31, 2023 (fiscal 2024 first quarter); comparison is the three months ended July 31, 2022. The company provides oncology research and drug-development services and related technology platforms, including its Lumin SaaS product. Amounts below are in U.S. dollars.
Key financial metrics
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Oncology services revenue | $12.561 million | $13.745 million |
| Cost of oncology services | $7.684 million | $7.052 million |
| Oncology services margin | 38.8% | 48.7% |
| Research and development | $2.793 million | $2.887 million |
| Sales and marketing | $1.696 million | $1.692 million |
| General and administrative | $2.940 million | $2.398 million |
| Operating loss | $2.552 million | $0.284 million |
| Net loss | $2.566 million | $0.319 million |
| Net loss per share, basic and diluted | $0.19 | $0.02 |
| Cash used in operating activities | $3.991 million | $0.195 million |
At July 31, 2023, cash and cash equivalents were $4.869 million, down from $10.118 million at April 30, 2023. Accounts receivable, net, was $8.948 million; deferred revenue was $11.142 million. Current assets totaled $14.922 million against current liabilities of $20.382 million. Stockholders’ equity was $1.903 million, and accumulated deficit was $79.883 million.
The filing reports no off-balance-sheet debt or similar obligations. It does report operating lease liabilities of $8.351 million in total ($1.244 million current and $7.107 million non-current); no conventional borrowing balance is identified in the provided financial statements. Investing activities used $0.668 million, primarily for lab and computer equipment; financing activities used $0.590 million, mainly for share repurchases.
Changes versus the prior comparable period
- Revenue decreased $1.184 million, or 8.6%. Management attributed the lower revenue conversion in the quarter to study cancellations during the prior year.
- Service costs rose 9.0% while revenue fell, reducing the reported services margin to 38.8% from 48.7%. Management cited outsourced lab services and a higher expense base on lower revenue conversion.
- Operating expenses increased 7.7% overall. General and administrative expense rose 22.6%, mainly from higher bad-debt expense and credit-loss provision (about $160,000) and non-cash stock compensation. R&D declined 3.3%; about $1.2 million of Q1 FY2024 R&D was directed to target discovery.
- Operating cash use increased to $3.991 million from $0.195 million. Management cited the operating loss, higher receivables due to ordinary-course timing, and lower deferred revenue associated with study cancellations.
- Cash declined $5.249 million during the quarter. The company repurchased approximately 115,000 shares for about $676,000 under its $5.0 million authorization; approximately $4.3 million remained available at quarter-end.
Outlook, risks and unusual items
- Management said cash on hand plus expected operating cash flows for the remainder of fiscal 2024 should fund operations for at least 12 months from the filing date. If revenue expectations are not met, it expects it could implement cost reductions; additional capital might be needed, with no assurance it could be raised on acceptable terms.
- No specific revenue or earnings guidance is provided. Management says it regularly evaluates strategic options for its drug-discovery business, potentially including spin-outs or capital raises; commercial strategy for validated targets and therapeutics remains under development.
- Liquidity and execution risks include the quarterly operating cash outflow, lower revenue conversion, the current-liability excess over current assets, and customer termination rights in many contracts. Cash deposits exceeded FDIC insurance limits by $4.7 million at July 31, 2023.
- The company recorded a $162,000 provision for doubtful accounts in the quarter; net receivables included an allowance of $986,000. A $181,000 liability for uncertain tax positions remained recorded. Management reported no current legal proceedings and no accrued liquidated damages under its registration-rights arrangement.
- The filing states disclosure controls were effective as of July 31, 2023, with no material changes in internal control over financial reporting during the quarter. Interim results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Whether revenue conversion and study cancellations improve, and whether service margins recover from 38.8%.
- Whether operating cash use moderates and management’s stated 12-month liquidity expectation remains supported by actual cash flows.
- Receivables collectability, the adequacy of the credit-loss allowance, and the trend in deferred revenue and unbilled services.
- Progress and funding needs for target discovery, Lumin, and potential strategic transactions; no specific guidance or transaction terms are disclosed.
- Future use of the remaining share-repurchase authorization in light of cash needs and the company’s liquidity position.